TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
new version V2017
Description
Results
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
in third
All mechanism
angiotensin-Converting Enzyme Inhibitors
angiotensin-receptor blockers
antioxydants
antithrombotics
HR-slowing agents
Induction chemotherapy
Larynx preservation
myocardial revascularization
stent
vasodilators therapy
atorvastatin
fluvastatin
lovastatin
pravastatin
rosuvastatin
simvastatin
captopril
ramipril
irbesartan
losartan
telmisartan
valsartan
candesartan
aleglitazar
ertugliflozin
semaglutide
alogliptin
apixaban
ardeparin
aspirin
biolimus eluting stent
bivalirudin
canagliflozin
Certoparin
clopidogrel
coumadin
dabigatran
dactinomycin eluting stent
dalteparin
dapagliflozin
drug-eluting stents
empagliflozin
enoxaparin
everolimus eluting stent
exenatide
fondaparinux
fraxiparin
glargine
linagliptin
liraglutide
lixisenatide
logiparin
nadroparin
olmesartan
paclitaxel
pioglitazone
reviparin
rivaroxaban
rt-PA
saxagliptin
sirolimus eluting stent
sitagliptin
streptokinase
tinzaparin
triflusal
UFH
urokinase
warfarin
zotarolimus eluting stent
Synopsis
Synopsis
Results
Treatments
Patients_
Method
References
Filters
Ongoing trials
Show ongoing trials
Hide ongoing trials
Risk of bias
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
Conclusive result
Show all trials
Show only trial with conclusive result
All cause death
Coronary death
Coronary event
Adverse events
Amputations
Bleeding
Cardiovascular death
Death from cancer
MACE
Fatal MI
Heart failure
In-hospital death
Revascularization
Long term death
Major bleeding
Minor bleeding
Haemmorhagic stroke
Fatal stroke
Non fatal stroke
Non fatal MI
Fatal bleeding
Cancer
Rhabdomyolysis
thrombo-embolic event (cerebral or systemic)
ischemic stroke
hypertransaminasemia
intracranial hemorrhage
TE event or ischemic stroke or systemic embolism
Serious adverse event
Non vascular death
Deaths or MI
stroke (fatal and non fatal)
myocardial infarction (fatal and non fatal)
Death from any cause or hospitalization for any reason
hospitalisation for heart failure
Cough
Recurrent thromboembolic event
Thrombus extension
Short term haemorrhage
Symptomatic pulmonary embolism
Deep vein thrombosis
Sudden death
cardiac death
reinfarction
cardiovascular events
cardiac event (fatal and non fatal )
A CHANGER
vomiting
diarrhoea
cancer related death
Stent thrombosis (any, end of follow up)
target lesion revascularisation
angiographic restenosis
4 yr mortality from all causes
4 yr TLR
4 yr MI
4 yr death or MI
4 yr stent thrombosis
4y stent thrombosis (ARC)
recurrent angina
Drop in platelet count of 50%
death, myocardial infarction, or recurrent at 14 days
CABG
PTCA
Hypotension
Adverse events leading to treatment discontinuation
angiodema
Coronary death and non fatal MI
Myopathy
LDL
Diabetes onset
non cardiovascular death
proximal DVT
distal DVT
non-fatal pulmonary embolism
asymptomatic DVT
total VTE and all-cause mortality
asymptomatic proximal DVT
Venous thromboembolism
wound haematoma / infection
fatal pulmonary embolism
All-cause hospitalisation
exacerbation of heart failure
macrovascular events
microvascular events
nephropathy
retinopathy
macrovascular or microvascular events
fatal HF
Peripheral vascular events
atrial fibrillation
Symptomatic venous thromboembolism (DVT, PE)
transfusion
recurrence of pulmonary embolism
stroke or TIA
Hospitalization for any reason
Recurrent DVT/DVT extension (symptomatic)
Thrombocytopenia
death at 3 months
reinfarction at 30 days
death at 30 days
TIA
myocardial infarction or death
death, myocardial infarction, or recurrent at 30 days
death at 30 days
myocardial infarction at 30 days
death, MI, unplanned revascularization
late stent thrombosis (31days - 1year)
target-vessel revascularization
2 yr TLR
2 yr MACE
in-lesion binary restenosis
2 yr Death (all cause)
Acute stent thrombosis (<=24h)
sub acute stent thrombosis (1-30 days)
Hyperkalaemia
Recurrent Symptomatic Venous Thromboembolism or death
Myocardial ischemia
recurrent symptomatic venous thromboembolism and death at the end of treatment
symptomatic venous thromboembolism at the end of treatment
major VTE (fatal and non fatal DVT,PE)
new-onset diabetes
death or cardiovascular hospitalization
Cardiovascular death or hospital admission for CHF
all cause death, MI, stroke
Gastrointestinal major bleeding
Non-lifethreatening major bleeding
Lifethreatening major bleeding
Symptomatic deep-vein thrombosis
change in HbA1c (%)
change in body weight (kg)
long term cardiovascular events
cardiovascular events at 4 months
cardiovascular events at 1 month
total cholesterol (at 1 y)
HDL (at 1 y)
major or clinically relevant non-major bleeding
hypertension
vision loss
severe hypoglycemia
net benefit
Unplanned revascularisation for ischaemia
HbA1c
all hypoglycemia
lung cancer
breast cancer
prostate cancer
any bleedings
systemic thrombo-embolic complication
HbA1c < 6.5%
HbA1c <7%
treatment-emergent adverse events (TEAEs)
serious adverse events
severe adverse events
change in daily mean glucose, mmol/L
change in FSG, mmol/L
recurrent VTE
Trial
Studied treatment
Control treatment
patients
ROB
Result
NCT
All mechanism
glargine
ORIGINE, 2012
insulin glargine
control
Negative
NCT00069784
HR-slowing agents
ivabradine
SHIFT, 2010
ivabradine
placebo
Low risk of bias
Suggesting
ISRCTN70429960
×
Modal title
